Quantum BioPharma Develops Two-Pronged Attack on Brain Disorders Affecting Millions

Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.

Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the world; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of men. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.

The company also developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product targets a common but underserved issue, offering a potential solution for millions who experience the negative effects of alcohol consumption.

Quantum BioPharma’s dual approach highlights its commitment to addressing neurological disorders with innovative therapies. The company continues to advance its pipeline, leveraging collaborations and proprietary science to bring new options to patients. For more information, visit the company’s newsroom at https://ibn.fm/QNTM.